Skip to main content
Premium Trial:

Request an Annual Quote

Eyeing Chinese IVD Market, OriGene Buys BioCheck


OriGene Technologies said this week that it has acquired Foster City, Calif.-based immunoassay firm BioCheck.

The acquisition expands Origene's in vitro diagnostic portfolio and capabilities for future product development, the company said. In particular, the purchase provides OriGene with IVD products for the Chinese clinical market, currently a major area of focus for the company.

According to OriGene, the Chinese IVD market is among the fastest growing in the world and is predicted to be the second largest globally by 2017.

"OriGene values BioCheck’s unique combination of novel [US Food and Drug Administration-cleared] diagnostic products and its custom immunoassay development platform," OriGene CEO Wei-Wu He said in a statement. "Gaining such capacity is crucial to OriGene’s mission to empower the Chinese IVD market with more specific and sensitive products for responsive decision making and improved health outcomes."

BioCheck has developed custom immunoassays for a variety of conditions, including colorectal cancer, breast cancer, osteoporosis, heart disease, and several infectious diseases.

The price of the acquisition and other terms of the deal were not disclosed.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.